[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Medical ISM (Integrative Systemic Medicine)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100642418",false,"NCT07637084","Photobiomodulation for Chronic Pain and Fatigue in Hypermobile Ehlers-Danlos Syndrome (PBM-SEDh-01)","Effect of MLS® Class IV Laser Photobiomodulation on Chronic Pain and Fatigue in Hypermobile Ehlers-Danlos Syndrome: A Prospective Observational Pilot Study in Private Medical Practice","PBM-SEDh-01","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Confirmed diagnosis of hypermobile Ehlers-Danlos Syndrome (hEDS) according to 2017 International Consortium criteria\n* Chronic pain ≥ 3 months, average VAS score ≥ 4\u002F10 over the preceding week\n* Stable analgesic treatment for ≥ 4 weeks (if any)\n* Follow-up at Centre Médical ISM, Boulogne-Billancourt\n* Informed and non-opposition signed\n\nExclusion Criteria:\n\n* Suspicious or malignant skin lesion on areas to be treated\n* Non-modifiable photosensitizing treatment\n* Pregnancy or breastfeeding\n* Photosensitive epilepsy\n* Acute articular inflammatory flare at inclusion date\n* Analgesic treatment modification within 4 weeks prior to inclusion\n* Simultaneous participation in another research protocol","ALL","18 Years",{"count":19,"type":20},25,"ESTIMATED","10 Weeks","OBSERVATIONAL","This study evaluates the effect of photobiomodulation (PBM) therapy using a MLS® class IV laser on chronic pain and fatigue in patients with hypermobile Ehlers-Danlos Syndrome (hEDS). hEDS is a hereditary connective tissue disorder characterized by joint hypermobility, chronic pain, and debilitating fatigue, for which therapeutic options remain limited.\n\nParticipants will receive 10 PBM sessions over 5 weeks (2 sessions per week), using red and near-infrared light (808 nm continuous + 905 nm pulsed) applied to painful areas identified at baseline. Pain (Visual Analogue Scale), multidimensional fatigue (MFI-20), and quality of life (EQ-5D-5L) will be assessed at baseline (T0), end of treatment (week 5), and follow-up (week 10).\n\nThis is a pilot observational study - the first to document the effect of MLS® laser PBM in hEDS. No additional procedures beyond routine care are required.",[25,26,27],"Ehlers-Danlos Syndrome, Hypermobile","Chronic Pain","Fatigue Syndrome, Chronic",[29],"photobiomodulation; laser therapy; MLS laser; Ehlers-Danlos syndrome; chronic pain; fatigue; quality of life; observational study; pilot study","RECRUITING","2026-06-11",{"date":33,"type":34},"2026-06-15","ACTUAL",{"date":36,"type":34},"2026-05-26",{"date":38,"type":20},"2027-09-30",{"name":40,"class":41},"Centre Medical ISM (Integrative Systemic Medicine)","OTHER",""]